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ICON3 trial results have suggested that CAP and carboplatin–taxol regimens as first-line treatment of advanced ovarian cancer
(AOC) yield similar survival. We explored the impact of increased dose of cyclophosphamide in a modified CAP regimen on the
disease-free survival (DFS) and overall survival (OS) of AOC patients. From February 1994 to June 1997, 164 patients were
randomised to receive six cycles every 3 weeks of either standard CEP (S) combining cyclophosphamide (C), 500mgm
 2, epirubicin
(E) 50mgm
 2, and cisplatin (P) 75mgm
 2 or intensive CEP (I) with E and P at the same doses, but with (C) 1800mgm
 2 and
filgrastim 5mgkg
 1 per day 10 days. Response was evaluated at second-look surgery. Patient characteristics were well balanced.
Except for grade 3–4 neutropaenia (S: 54%, I: 38% of cycles), Arm1 presented a significantly more important toxicity: infection
requiring antibiotics, grade 3–4 thrombocytopaenia, anaemia, nausea-vomiting, diarrhoea, mucositis. Median follow-up was 84
months. DFS (15.9 vs 14.8 months) and OS (33 vs 30 months) were not significantly different between S and I (P40.05). Increasing
cyclophosphamide dose by more than 3 times with filgrastim support in the modified CAP regimen CEP induces more toxicity but
not better efficacy in AOC.
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Advanced ovarian cancer (AOC) is considered one of the most
chemotherapy-sensitive epithelial malignant tumours (Ozols and
Young, 1991; Trimble et al, 1994). First-line regimens with a
platinum salt used alone or in combination (McGuire et al, 1996;
Muggia et al, 2000) induce objective response in more than half of
the patients. However, a majority ultimately relapse after a median
interval which rarely exceeds 18 months (McGuire et al, 1996)
suggesting the need of new therapeutic regimens.
In the 1990s, the combination of cisplatin and paclitaxel was
established as first-line therapy for AOC patients after two large
phase III trials had demonstrated the superiority of this
combination over the then standard regimen of cyclophosphamide
and cisplatin (McGuire et al, 1996; Piccart et al, 2000). A number
of studies have evaluated the combination of paclitaxel and
carboplatin as an alternative to the paclitaxel–cisplatin regimen
(Neijt et al, 2000; Bookman et al, 2003; Ozols et al, 2003). They
have shown that the carboplatin combination is associated with
a lower incidence of non-haematologic toxicities (particularly
neurotoxicity) and better quality of life, whereas no significant
difference in progression-free survival (PFS) and overall survival
(OS) was detected. From these findings, the International
Consensus Conference in Ovarian cancer, held in Baden-Baden
in 2004, concluded that carboplatin–paclitaxel was the first-line
standard for AOC treatment.
This consensus however has been challenged by the results of
two randomised trials comparing platinum–paclitaxel to alter-
native regimens. The GOG 132 study compared cisplatin alone
(100mgm
 2), paclitaxel alone (200mgm
 2 over 24h), and the
combination of the two agents (paclitaxel 135mgm
 2 followed by
cisplatin 75mgm
 2) in 614 women with stage III or IV disease
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the combination arm and the cisplatin-alone arm. The ICON3 trial
enrolled 2074 patients with stage I through stage IV ovarian cancer
who were randomised to receive carboplatin (dosed to AUC 6) in
combination with paclitaxel (175mgm
 2 over 3h), or a control of
carboplatin (dosed to AUC 6) alone or the combination of
cyclophosphamide (500mgm
 2), doxorubicin (50mgm
 2), and
cisplatin (50mgm
 2) (CAP regimen) (ICON, 2002) no significant
OS or PFS differences were between the groups. These data suggest
that, at least in certain circumstances, platinum used as a single
agent or in combination within a CAP regimen might be as
effective as the standard paclitaxel–platinum doublet.
One approach to improve the results of chemotherapy in the
first-line setting would be to optimise platinum-based regimens by
increasing drug dose intensity. However, most prospective trials
exploring an increase of platinum dose intensity in AOC have
given negative results, suggesting that no significant benefit could
be obtained with doses over 75–100mgm
 2 for cisplatin and AUC
5–7.5 for carboplatin (Levin et al, 1993).
One alternative option would be to explore the impact of
increasing cyclophosphamide doses within a platinum-based
regimen. The dose-limiting factor of cyclophosphamide is
haematological toxicity, particularly neutropaenia. Severe neutro-
paenia can be improved by the administration of granulo-
cytecolony stimulating factors (G-CSF), allowing to increase
cyclophosphamide dose to a magnitude not attainable by platinum
compounds because of their non-haematological or platelet dose-
limiting toxicity.
These observations prompted the GINECO group to test the
efficacy of chemotherapy using intensified doses of cyclophos-
phamide in combination with cisplatin and epirubicin against the
same chemotherapy with standard doses of each drug.
PATIENTS AND METHODS
Study design
This study was an open, comparative, multicentric, phase III study.
The primary end point was to determine the impact of increased
doses of cyclophosphamide supported by filgrastim in a modified
CAP regimen (CEP) on the OS of International Federation of
Gynaecology and Obstetrics (FIGO) stage III–IV epithelial AOC
patients. Secondary end points included evaluation of disease-free
survival (DFS), patterns of recurrence, response rate, and toxicity.
Patient selection
Eligible patients included patients with histologically documented,
chemotherapy-naı ¨ve ovarian epithelial carcinoma. Other require-
ments included: age 18–70 years, World Health Organization
(WHO) performance status p2, FIGO stage III or IV, satisfactory
haematological, renal, cardiac and hepatic functions, and initiation
of chemotherapy within 4 weeks after initial laparotomy. Exclusion
criteria were previous malignant tumour (except for treated basal
cell skin cancer or in situ cervical cancer), history of nervous or
psychiatric disorder that would preclude informed consent or
compliance, infection, or severe disease including intestinal
occlusion, bilirubin level 41.25 times upper normal limit,
transaminases 42.5 times upper normal limit except for patients
with liver metastases, white blood cell count o3.5 10
9 per l,
granulocyte count o2.0 10
9 per l, platelet count o100 10
9 per
l, serum creatinine 4120mmoll
 1, symptomatic cardiomyopathy
or cerebral metastasis. All patients gave written informed consent
approved from regulatory authorities and ethics committees before
taking part in the study.
Patients were stratified according to stage and size of the
residual lesion after initial surgery: stage III and microscopic
residuals, or stage III and o2cm residuals, or stage III and 42cm
residuals, or stage IV. They were randomly assigned to receive
either intensified or standard chemotherapy.
Pre-treatment and treatment evaluation
Thoracic radiography and computed tomographic scans of the
abdomen and the pelvis were performed after surgery (if realised)
within 4 weeks before entry into the study. Medical history, clinical
examination, performance status assessment, electrocardiogram,
ventricular ejection fraction (VEF) and blood tests (complete
blood cell count, serum creatinine, bilirubin, transaminases,
alkaline phosphatases, and CA-125) were performed within 2
weeks. Blood cell and platelet counts were repeated weekly.
Physical examination, serum CA-125 level, WHO grade toxicity
assessment and blood tests were performed on day 1 of each cycle.
Radiological examinations, to document the status of the disease at
baseline, and serum CA-125 levels were repeated systematically at
the end of the program and whenever necessary. For patients with
clinical and tumour marker complete responses, treatment was
followed by a second-look laparotomy.
Treatment
Treatment schedule Eligible patients were randomised to receive
six cycles of either standard CEP (S) or intensive CEP (I).
follow-up
Cyclophosphamide = 1800 mg m−2  
Epirubicin = 50 mg m–2
Cisplatin = 75 mg m–2 
Filgrastim = 5 g kg–1 day–1, sc, D2-11 
Cyclophosphamide = 500 mg m−2 
Epirubicin = 50 mg m–2 
Cisplatin = 75 mg m–2 
Intensive 
CEP (I)
Standard 
CEP (S)
6 courses  
In the standard treatment arm (S) patients received at day 1 of
each cycle: cyclophosphamide (ENDOXAN
s) 500mgm
 2 admi-
nistered as a 30-min intravenous infusion, followed by epirubicin
(FARMORUBICINE
s)5 0m gm
 2 as a bolus infusion, and cisplatin
(CISPLATYL
s)7 5 m g m
 2 diluted in 500ml of normal saline
delivered as a 30-min intravenous infusion. Hydration with
isotonic solution (3l on day 1) was systematically realised for
each cycle. In the intensified treatment arm (I) patient received, at
day 1 of each cycle, a combination of cyclophosphamide
(ENDOXAN) 1800mgm
 2 administered as a 30-min intravenous
infusion after hyperhydration, followed by epirubicin (FARM-
ORUBICINE) 50mgm
 2 and cisplatin CISPLATYL) 75mgm
 2.
Hydration with isotonic solution (3l on day 1) was systematically
realised for each cycle, but mesna rescue was not forecasted.
Filgrastim (NEUPOGEN
s)5 mgkg
 1 per day was administered
from day 2 to day 11 of each cycle in the intensified arm. Filgrastim
was not proposed in the standard arm, reduction of dose should be
considered before.
Cycles were repeated every 3 weeks. A number of six cycles was
planned, up to a maximum of nine cycles. All patients received
prophylactic anti-emetic therapy with 5HT3 inhibitors.
Toxicity and dosage modification guidelines
Toxicity was evaluated according to the WHO criteria (Perry,
1992). When patients experienced febrile neutropaenia, prolonged
grade 4 neutropaenia (47 days) or grade 4 thrombopaenia, doses
of cyclophosphamide were reduced by 20% in the subsequent
cycles. Doses of cisplatin were also reduced by 20% in case of grade
2 neurotoxicity. Doses of epirubicin and cyclophosphamide were
also reduced by 20% in case of grade 2 stomatitis. A similar dose
reduction of the three drugs was necessary in case of any grade 3
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snon-haematological toxicity, except digestive toxicity. Chemo-
therapy was stopped in case of symptomatic heart failure and
creatinine serum level 4150mmoll
 1.
Follow-up
After treatment, patients were followed every 3 months during
3 years, then every 6 months up to 5 years, and every year
thereafter. Routine evaluations at each follow-up visit included
physical examination and serum CA-125 level.
Efficacy criteria
PFS was measured from the date of protocol entry to the date of
first progression or death or to the date of last contact for patients
who are alive and progression-free. OS was defined as the time
from random assignment to death or last contact.
Clinical response was evaluated according to the WHO criteria.
Those patients who were in complete clinical and serological
response at the end of chemotherapy were submitted to a second-
look laparotomy. Complete pathological response was defined as
the absence of macroscopic and microscopic tumour lesion. Partial
pathological response was defined as the persistence of micro-
scopic lesions at second-look laparotomy in patients with residual
macroscopic lesions after initial surgery, or a reduction of
macroscopic lesions according to the WHO criteria.
Statistical analysis
The study was designed to detect a difference of 15% in OS at
2 years from an expected 2-year OS of 50% in the standard arm.
With a statistical power of 0.90 and a type I error of 0.05, this
difference would require the inclusion of 195 patients in each arm.
Statistical analysis was performed using SPSS
s 9.0 software (SPSS
Inc., Chicago, IL, USA 1999) and P-values less than 0.05 (two-sided
test) were considered statistically significant. Patients who with-
drew before completion of the study treatment or who were
declared ineligible (n¼9) were excluded from the primary
analyses of toxicity and second look. Frequency tables and
summary statistics (e.g., mean and median) were used to describe
the distributions of patient characteristics and toxicity. Parametric
and w
2 tests were used to test for significant differences in patient
characteristics and toxicity between treatment arms. The Kaplan–
Meier method was used to estimate the distributions of DFS and
OS (Kaplan, 1958). Cox proportional hazards models were used to
explore the associations of patient characteristics (e.g. stage and
residual tumour) with patient outcome (e.g. survival) (Mantel,
1959). The score statistic was used to test for a significant
difference in patient outcome on the basis of a single covariate (e.g.
sex). The likelihood ratio test was used to test for the significance
of a single covariate in the presence of (or adjusting for) other
covariates.
RESULTS
Enrolment began in February 1994 and was stopped in June 1996
with a lower than expected accrual of 164 patients. The main
reason for this low accrual was the approval of paclitaxel in first
line in the course of study enrolment. Of the 164 accrued patients,
155 were eligible and assessable, 5 had non-epithelial ovarian
cancer (S (2), I (3)), 1 (I) had cardiac failure at study entry and 3
withdrew their consent before treatment (S (1), I (2)).
Patient characteristics are summarised in Table 1. The two
treatment arms were well matched with respect to demographics
and disease characteristics. Interestingly, like in other published
series (Hoskins et al, 1994) less than 50% of included patients
benefited of optimal debulking surgery.
Overall and progression-free survival
The primary end point of the study (OS at 2 years) was 66% for the
standard arm and 64% for the intensified arm (P¼0.7). The
median survival duration was 31.1 months (range 27.2–35.0) for
the whole cohort. It was 32.5 months (CI 95% 27.3–37.7) for
patients in the standard arm, and 30 months (CI 95% 24.7–35.7)
for patients in the intensified arm (P¼0.6) (Figure 1). Median PFS
for patients receiving the standard treatment was 15.9 months (CI
95% 12.3–19.5) vs 14.8 months (CI 95% 11.8–17.8) for patients in
the intensified treatment arm (P¼0.55) (Figure 2).
In a univariate analysis, PFS was correlated to presence of
residual lesions after initial surgery (no or microscopic lesion vs
less than 2cm vs more than 2cm) (P¼0.005) and to initial FIGO
stage (P¼0.05), but not to age at diagnosis, histological subtype,
treatment arm, or performance status. Multivariate Cox model
analysis showed that only residual lesion size after initial surgery
was a significant independent prognostic factor for PFS, with a
median of 33.7 months for patients without macroscopic residual
lesion and 14.9 months for patients with macroscopic residual
lesions (P¼0.003).
Regarding OS, the univariate analysis identified significant
prognostic values for FIGO stage (P¼0.02), residual lesion size
(P¼0.016), and performance status (P¼0.015), but not for age
(P¼0.34), treatment arm (P¼0.61), or histological subtype
(P¼0.21). In a Cox model analysis, only residual lesion size after
initial surgery remained statistically significantly correlated to OS
(P¼0.024) with a median survival of 46.2 months for patients
without macroscopic residual lesion and 30.4 months for patients
with macroscopic residual lesions.
Table 1 Patient characteristics
CEP
Standard (S) Intensive (I) P
Patient number (%) 85 (100%) 79 (100%)
Median age (range), in years 60 (23–70) 59 (23–70) 0.46
WHO performance status 0.66
0 24 (28%) 17 (22%)
1 48 (56%) 50 (63%)
2 13 (16%) 12 (15%)
FIGO stage 0.43
IIIA+B 22 (26%) 22 (28%)
IIIC 44 (52%) 42 (53%)
IV 19 (22%) 15 (19%)
Presence of ascites 31 (36%) 39 (49%) 0.15
Histologic type 0.72
Serous 59 (69%) 53 (67%)
Endometrioid 10 (12%) 6 (8%)
Others 16 (19%) 20 (25%)
Histologic grade 0.81
1 19 (22%) 16 (20%)
2 23 (27%) 22 (28%)
3 20 (24%) 22 (28%)
Unknown 23 (27%) 19 (24%)
Size of residual lesion after surgery 0.77
Microscopic 12 (15%) 8 (10%)
o2cm 26 (30%) 25 (32%)
X2cm 47 (55%) 46 (58%)
Abbreviation: FIGO¼International Federation of Gynaecology and Obstetrics.
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Among the 155 patients assessable for clinical and tumour marker
response, only 114 (74%) had a second-look laparotomy. The
reasons why second-look laparotomy was not performed in the
other 41 patients are detailed in Table 2; reasons were equally
distributed between the two arms.
Of the 114 patients who had a second-look laparotomy, 25 out
of 63 (39%) in the standard group and 12 out of 51 (23%) in the
intensified group achieved a pathological complete response (pCR)
(P¼0.46). Also, no statistical difference was noted between the two
groups of patients; the intensified arm resulted in less pCR and
more macroscopic residual disease. However, no information in
the database provided any basis for formulating hypotheses or
postulating causes, such as dose reduction, treatment delay, or
patients or initial surgical characteristics.
Toxicity
A total of 830 courses were administered (447 in S and 383 in I).
The ratio of the delivered dose to the planned dose was cisplatin (S
(0.99), I (0.98)), epirubicin (S (0.99), I (0.98)) and cyclophos-
phamide (S (0.99), I (0.94)). A total of 65 patients (78%) in the
standard arm and 56 (77%) in the intensive arm received the six
planned courses. No patient in either arm received more than six
cycles. A dose reduction in one of the drugs was performed in 31
(15%) cycles: 20% dose reduction in 11 (5%) cycles, and 40% dose
reduction in 20 (10%) cycles. In 30 out of 31 cases, dose reduction
was decided because of haematotoxicity.
Chemotherapy was stopped in 34 patients, 17 in each arm.
Causes of early treatment stop were as follows:
  Standard arm: toxic death [1], progressive disease [4], nausea/
vomiting [1], hypersensitivity [1], elevated creatinine [1],
haematological toxicity [2], others [7].
  Intensive arm: toxic death [2], progressive disease [3], cardiac
arrhythmia [1], elevated creatinine [1], elevated alkaline
phosphatases [1], haematological toxicity [1], fatigue [1],
others [7].
Main WHO grade 3–4 toxicities are shown in Table 3.
Compared to standard treatment, patients receiving intensive
treatment and filgrastim support experienced a lower rate of grade
3 out of 4 neutropaenia but more frequent severe thrombopaenia
and anaemia. The rate of severe infection and mucositis was
significantly superior in patients receiving intensified treatment.
Grade 2 peripheral neuropathy was observed in 2 out of 82
patients of group S (2%) and in 3 out of 73 patients of group I
(4%); no grade 3 was observed. Grade 2 alopecia was observed in
Disease-free survival
S arm
I arm
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Figure 2 Median PFS for patients receiving the standard treatment was
15.9 months vs 14.8 months for patients in the intensified treatment arm
(P¼0.55).
Table 2 Second-look laparotomy (SLL)
No. of evaluable patients (n¼155)
Standard (S)
n¼82
Intensive (I)
n¼73
SLL (n¼114) 63 (77%) 51 (70%)
Findings
pCR 25 (39%) 12 (23%)
Microscopic 11 (17%) 12 (24%)
o2cm 16 (25%) 15 (29%)
42cm 11 (18%) 12 (24%)
Not done (n¼41) 19 (23) 22 (30)
Reasons
Stable/progressive disease 4 (21%) 3 (14%)
Early stopping due to toxicity 6 (32%) 7 (32%)
Patient refusal 1 (5%) 3 (14%)
Others 8 (42%) 9 (41%)
Abbreviation: pCR¼pathological complete response.
Table 3 WHO grade 3 out of 4 toxicities
% of patients
Standard (S) n¼82 Intensive (I) n¼73 P
Leucopaenia 33 (40%) 40 (55%) 0.07
Neutropaenia 53 (65%) 37 (51%) 0.07
Anaemia 17 (21%) 31 (42%) 0.003
Thrombocytopaenia 10 (12%) 24 (33%) 0.001
Nausea-vomiting 25 (30%) 24 (33%) 0.74
Diarrhoea 0 3 (4%) 0.06
Constipation 1 (1%) 3 (4%) 0.25
Mucositis 0 1 (2%) 0.28
Infections 2 (2%) 11 (15%) 0.004
80 60 40 20 0
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Overall survival
S arm
I arm
Figure 1 Median survival duration was 32.5 months for patients in the
standard arm and 30 months for patients in the intensified arm (P¼0.6).
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Grade 2 serum creatinine elevation was observed in one patient of
group S (1%) and three patients of group I (4%).
DISCUSSION
A total of 164 AOC patients were randomised to receive six cycles
of CEP regimen every 3 weeks, with either standard cyclophos-
phamide dose (500mgm
 2), or intensive dose (1800mgm
 2) with
filgrastim support.
Toxicity was higher, with more frequent severe thrombopaenia
and anaemia, in the intensive than that in the standard treatment
arms. Despite a lower rate of severe neutropaenia, more severe
infections and mucositis were reported in patients receiving
intensive cyclophosphamide. Interestingly, this increased toxicity
was not associated with increased mortality and did not
compromise the total drug dose or number of cycles. Thus,
increasing doses of cyclophosphamide up to over 3 times, the
standard dose is possible in patients with ovarian cancer within a
first-line CEP regimen.
However, patients treated with the CEP regimen derived no
benefit from this higher cyclophosphamide dose. PFS and OS rates
were not superior for patients treated in the intensive arm
compared to those in the standard arm. One of the limitations to
these results is the small size of the patient sample studied.
Nevertheless, it is very unlikely that a larger cohort would have
allowed proving a superior efficacy of intensified cyclophos-
phamide dose compared to standard dose. None of the efficacy
criteria tested indicated a superiority of the intensive arm over the
standard. The rates of complete pathological response at second-
look laparotomy, PFS and OS were all slightly inferior in patients
treated with intensive cyclophosphamide. A possible explanation
could be derived from the fact that the intensified arm resulted in
less pCR and more macroscopic residual disease; however, this was
an intriguing finding.
This study addressed two important issues for the management
of first-line chemotherapy in ovarian cancer patients: the impact of
high-dose therapy and the role of cyclophosphamide. The recent
results of high-dose chemotherapy, including high-dose cyclophos-
phamide supported by peripheral blood stem cell transplantation,
have yielded disappointing results in the first-line treatment of
ovarian cancer. H Cure ´ and the GINECO group have shown no
benefit of high-dose carboplatin–cyclophosphamide over standard
dose used as consolidation therapy in patients responding to first-
line chemotherapy (Cure et al, 2004). Recently, Lederman et al
(2005) reported the results of a phase III study of multi-cycle high-
dose chemotherapy vs standard platinum-based chemotherapy in
predominately optimally debulked stage IIB to IV epithelial
ovarian cancer. Their data did not show a short-term benefit of
the high-dose arm. There is currently no evidence of a benefit of
intensive chemotherapy in ovarian cancer.
The results of the present study may contribute to the debate on
the role of cyclophosphamide in the first-line setting. Before the
introduction of paclitaxel in first-line, platinum combinations were
considered more effective than single-agent platinum when the
drug was used at the same dose (AOCT, 1991). The association of
cyclophosphamide and cisplatin was adopted at that time as a
standard and served as a control in the first two trials exploring the
impact of paclitaxel–cisplatin combinations. However, the benefit
of platinum combinations compared to single-agent platinum has
long been debated; the analysis published by the Advanced
Ovarian Cancer Trialists Group showed that the difference between
the two regimens was at the limit of significance (ORR 0.85; CI
95%: 0.72–1.00) (AOCT, 1991). In addition, the ICON2 trial
conducted in a large population of AOC patients failed to
demonstrate an outcome advantage for patients treated with the
CAP regimen compared to carboplatin monotherapy (ICON,
1998). The debate was revisited after the results of the four
randomised trials exploring the role of paclitaxel in combination
with platinum. Two of these trials used cyclophosphamide plus
cisplatin as control and reported an advantage for the paclitaxel
combination. In contrast, the other two trials using single-agent
platinum as control did not show any benefit of the platinum–
paclitaxel combination over platinum alone. From the analysis of
these four trials, it has been hypothesised that a detrimental role of
cyclophosphamide might explain the discordant results observed
(Buyse et al, 2003). Our current data are not in favour of this
negative impact of cyclophosphamide on patient survival for doses
at least three-fold higher than standard doses, but all doses of
cyclophosphamide may still impact negatively on the efficacy of
cisplatin. Cisplatin dose was 75mgm
 2 in both arms of the study.
In conclusion, this is the only published study evaluating the
dose intensity of cyclophosphamide and the two treatment arms
have shown no significant difference in terms of second-look
findings, complete pathological response, PFS, and OS. Our data
do not support an increase of cyclophosphamide dose in a
modified CAP regimen (CEP) for the first-line treatment of
advanced AOC.
ACKNOWLEDGEMENTS
The authors thank Nathalie Le Fur and Christiane Pule ´o for data
management and M-Dominique Reynaud for editing assistance.
Authorship section
Isabelle Ray-Coquard, investigator, analysis of data, and writer,
De ´sire ´ Paraiso analysis of data, Jean-Paul Guastalla concept and
investigator, B Leduc investigator, F Guichard investigator, C
Martin investigor, L Chauvenet investigator, Z Haddad-Guichard
investigator, D Lepille ´ investigator, H Orfeuvre investigator, H
Gautier investigator, D Castera investigator, E ´ric Pujade-Lauraine
concept, analysis of data, and writing.
REFERENCES
AOCT Group (1991) Chemotherapy in advanced ovarian cancer: an
overview of randomised clinical trials. Advanced Ovarian cancer trialists
group. BMJ 303: 884–893
Bookman MA, Greer BE, Ozols RF (2003) Optimal therapy of advanced
ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel
(GOG 158) and an update on GOG0 182-ICON5. Int J Gynecol Cancer 13:
735–774
Buyse M, Burzykowski T, Parmar M, Torri V, Omura G, Colombo N,
Williams C, Conte P, Vermorken J, International Collaborative Ovarian
Neoplasm Collaborators (2003) Ovarian cancer meta-analysis project.
Using the expected survival to explain differences between the results of
randomized trials: a case in advanced ovarian cancer. J Clin Oncol 21:
1682–1687
Cure H, Battista RN, Guastalla J, Fabbro M, Tubiana N, Bourgeois H,
Pujade-Lauraine E (2004) Phase III randomized trial of high-dose
chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as
consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-
year follow-up of a GINECO/FNCLCC/SFGM-TC study. J Clin Oncol, 2004
ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22: 14S [5006]
Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT,
Berman M, Ball H, Berek JS (1994) The effect of diameter of largest
residual disease on survival after primary cytoreductive surgery in
patients with suboptimal residual epithelial ovarian carcinoma. Am J
Obstet Gynecol 170: 974–979
International Collaborative Ovarian Neoplasm Group (1998) ICON2:
randomised trial of single-agent carboplatin against three-drug combi-
Treatment of advanced ovarian cancer
I Ray-Coquard et al
1204
British Journal of Cancer (2007) 97(9), 1200–1205 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
snation of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women
with ovarian cancer. ICON collaborators. International collaborative
ovarian neoplasm study. Lancet 352: 1571–1576
International Collaborative Ovarian Neoplasm Group (2002) Paclitaxel plus
carboplatin versus standard chemotherapy with either single-agent
carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women
with ovarian cancer: the ICON3 randomised trial. Lancet 360: 505–515
Kaplan ECMP (1958) Non parametric estimation from incomplete
observations. J Am Stat Assoc 53: 437–481
Ledermann JA, Frickhofen N, Wandt H, Bengala C, Champion KM, Hinke A,
Moebus V (2005) A phase III randomised trial of sequential high dose
chemotherapy (HDC) with peripheral blood stem cell support or standard
dose chemotherapy (SDC) for first-line treatment of ovarian cancer. JC l i n
Oncol, 2205 ASCO Annual Meeting Proceedings 23: 16S [5006]
Levin L, Simon R, Hryniuk W (1993) Importance of multiagent
chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
J Natl Cancer Inst 85: 1732–1742
Mantel NHW (1959) Statistical aspects of the analysis of data from
retrospective studies of disease. J Natl Cancer Inst 22: 719–748
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY,
Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin
compared with paclitaxel and cisplatin in patients with stage III and
stage IV ovarian cancer. N Engl J Med 334: 1–6
Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez
RD, Kucera PR, Small JM (2000) Phase III randomized study of cisplatin
versus paclitaxel versus cisplatin and paclitaxel in patients with
suboptimal stage III or IV ovarian cancer: a gynecologic oncology group
study. J Clin Oncol 18: 106–115
Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de
Swart CA, Hirsch FR, Lund B, van Houwelingen HC (2000) Exploratory
phase III study of paclitaxel and cisplatin versus paclitaxel and
carboplatin in advanced ovarian cancer. J Clin Oncol 18: 3084–3092
Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA,
Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial
of carboplatin and paclitaxel compared with cisplatin and paclitaxel in
patients with optimally resected stage III ovarian cancer: a gynecologic
oncology group study. J Clin Oncol 21: 3194–3200
Ozols RF, Young RC (1991) Chemotherapy of ovarian cancer. Semin Oncol
18: 222–232
Perry MC (1992) Appendix-WHO toxicity guidelines. In The Chemotherapy
Sources Book, Perry MC (ed) pp 1132–1144. Baltimore: Williams &
Wilkins Inc
Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart
G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD,
Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F,
Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B,
Pecorelli S (2000) Randomized intergroup trial of cisplatin-paclitaxel
versus cisplatin–cyclophosphamide in women with advanced epithelial
ovarian cancer: three-year results. J Natl Cancer Inst 92: 699–708
Trimble EL, Arbuck SG, McGuire WP (1994) Options for primary
chemotherapy of epithelial ovarian cancer: taxanes. Gynecol Oncol 55:
S114–S121
Treatment of advanced ovarian cancer
I Ray-Coquard et al
1205
British Journal of Cancer (2007) 97(9), 1200–1205 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s